Comparing ReWalk Robotics (NASDAQ:LFWD) and Demant A/S (OTCMKTS:WILYY)

ReWalk Robotics (NASDAQ:LFWD) and Demant A/S (OTCMKTS:WILYY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ReWalk Robotics and Demant A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReWalk Robotics	0	0	1	0	3.00
Demant A/S	0	1	3	0	2.75

ReWalk Robotics currently has a consensus target price of $9.00, indicating a potential upside of 80.36%. Given ReWalk Robotics’ stronger consensus rating and higher probable upside, analysts plainly believe ReWalk Robotics is more favorable than Demant A/S.

Valuation and Earnings

This table compares ReWalk Robotics and Demant A/S’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReWalk Robotics	$13.85 million	3.06	-$22.13 million	($2.87)	-1.74
Demant A/S	$3.26 billion	3.12	$260.63 million	N/A	N/A

Demant A/S has higher revenue and earnings than ReWalk Robotics.

Volatility and Risk

ReWalk Robotics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, Demant A/S has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares ReWalk Robotics and Demant A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReWalk Robotics	-159.76%	-28.19%	-23.29%
Demant A/S	N/A	N/A	N/A

Insider & Institutional Ownership

26.8% of ReWalk Robotics shares are owned by institutional investors. 2.1% of ReWalk Robotics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Demant A/S beats ReWalk Robotics on 7 of the 12 factors compared between the two stocks.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.